ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time):

• The Canaccord Genuity 42^nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m.
• The 2022 Wells Fargo Healthcare conference on Friday, September 9, 2022, at 8:00 a.m.
• The Morgan Stanley 20^th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 3:30 p.m.
• The Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:15 p.m.

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

More on Boston Chron

• Boston: Mayor Wu Extends Heat Emergency Through Tuesday, 16 BCYF Cooling Centers Continue to Be Open for All Residents
• YUPRO and OpenClassrooms Introduce U.S. Department of Labor Registered Apprenticeship Program
• Boston: MAYOR WU APPOINTS OLIVER SELLERS-GARCIA AS BOSTON GREEN NEW DEAL DIRECTOR
• Triverus Consulting Welcomes Lisa Burgese Fry as Director of Business Development
• Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's latest innovation, the Omnipod^® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

More on Boston Chron

• Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
• Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
• HWS Announces Top 10 Low Cost Vacation Spots
• Boston: Mayor Wu Extends Heat Emergency Through Monday, 16 BCYF Cooling Centers Continue to Be Open to All Residents
• World's First Walkie-Talkie Bone Conduction Sport Headphones

©2022 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation.

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Merrill Robichaud
Investor Relations Coordinator
(978) 932-0444
mrobichaud@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

---

Show All News | Report Violation